Costantini M, Musso M, Viterbori P, Bonci F, Del Mastro L, Garrone O, Venturini M, Morasso G
Unit of Clinical Epidemiology and Trials, National Cancer Institute, Genoa, Italy.
Support Care Cancer. 1999 May;7(3):121-7. doi: 10.1007/s005200050241.
The psychometric properties of the Italian version of the Hospital Anxiety and Depression Scale and its utility as a screening instrument for anxiety and depression in a non-psychiatric setting were evaluated. The questionnaire was administered twice to 197 breast cancer patients randomised in a phase III adjuvant clinical trial: before the start of chemotherapy and at the first follow-up visit. The presence of psychiatric disorders was evaluated at the follow-up visit using the Structured Clinical Interview for DSM-III-R in 132 patients. Factor analyses identified two strictly correlated factors. Crohnbach's alpha for the anxiety and depression scales ranged between 0.80 and 0.85. At follow-up, 50 patients (38%) were assigned a current DSM-III-R diagnosis, in most cases adjustment disorders (24%) or major depressive disorder (10%). Receiver operating characteristics (ROC) analysis was used to test the discriminant validity for both anxiety and depressive disorders. The comparison of the areas under the curve (AUC) between the two scales did not show any difference in identifying either anxiety (P = 0.855) or depressive disorders (P = 0.357). The 14-item total scale showed a high internal consistency (alpha = 0.89 and 0.88) and a high discriminating power for all the psychiatric disorders (AUC = 0.89; 95% CI = 0.83-0.94). The cut-off point that maximised sensitivity (84%) and specificity (79%) was 10. These results suggest that the total score is a valid measure of emotional distress, so that the Italian version of HADS can be used as a screening questionnaire for psychiatric disorders. The use of the two subscales as a 'case identifier' or as an outcome measure should be considered with caution.
对意大利版医院焦虑抑郁量表的心理测量特性及其作为非精神科环境中焦虑和抑郁筛查工具的效用进行了评估。在一项III期辅助临床试验中,对197名随机分组的乳腺癌患者进行了两次问卷调查:化疗开始前和首次随访时。在随访时,使用针对DSM-III-R的结构化临床访谈对132名患者的精神疾病情况进行了评估。因子分析确定了两个高度相关的因子。焦虑和抑郁量表的克朗巴赫α系数在0.80至0.85之间。随访时,50名患者(38%)被诊断为当前的DSM-III-R疾病,大多数情况下为适应障碍(24%)或重度抑郁症(10%)。采用受试者工作特征(ROC)分析来检验焦虑和抑郁障碍的判别效度。两个量表曲线下面积(AUC)的比较在识别焦虑(P = 0.855)或抑郁障碍(P = 0.357)方面均未显示出差异。14项总量表显示出较高的内部一致性(α = 0.89和0.88)以及对所有精神疾病的高区分能力(AUC = 0.89;95%CI = 0.83 - 0.9)。使敏感性(84%)和特异性(79%)最大化的截断点为10。这些结果表明总分是情绪困扰的有效度量,因此意大利版HADS可作为精神疾病的筛查问卷。将两个子量表用作“病例识别工具”或结果测量指标时应谨慎考虑。